Jubilant Life Sciences, Tata Communications in Rakesh Jhunjhunwala's basket

In this quarter, Jhunjhunwala booked profit in information technology (IT) firm Firstsource Solutions (FSL) and raised his stake in pharmaceutical firm Jubilant Life Sciences

Topics
Jubilant Life Sciences | Tata Communications

Saloni Goel  |  New Delhi 

Markets may correct in the short term. But in a bull market the correction is always sharp, swift and short-lived: Rakesh Jhunjunwala
Jhunjhunwala, known as the Big Bull who invests both in his name and that of his wife, Rekha Jhunjhunwala, picked up a stake in Tata Communications during the third quarter

Investor Rakesh Jhunjhunwala, known for spotting multi-baggers, has increased stakes in two firms and offloaded in one, the latest available shareholding data for the October-December quarter (Q3) shows.

His name figured as a minority shareholder in

Jhunjhunwala, known as the Big Bull who invests both in his name and that of his wife, Rekha Jhunjhunwala, picked up a stake in during the third quarter.

According to the latest shareholding filed by the company, Rekha Jhunjhunwala held a 1.12 per cent stake, or 3.2 million shares, in at the end of Q3. As of September, her name did not appear among the shareholders.

Firms are mandated to post the names of shareholders having 1 per cent or more in them.

Jhunjhunwala held a stake in four other Tata Group firms, namely Tata Motors (1.29 per cent), Titan (5.52 per cent), Indian Hotels Company (1.05 per cent), and Rallis India (10.31 per cent) as of September. These firms are yet to report their shareholding patterns for the December quarter.

chart

Besides this, the ace investor also picked up shares in despite its underperformance vis-a-vis the Nifty during Q3. Jhunjhunwala hiked his stake to 5.82 per cent from 5.74 per cent at the end of the September quarter.

Shares of the pharma firm have risen 15.58 per cent in October-December as against a 24.30 per cent rise in the Nifty. The scrip has, however, zoomed nearly 300 per cent since its 52-week-low hit on March 30.

Analysts at Nirmal Bang see single-digit growth in specialty revenues on improvement in contract manufacturing and the life sciences business. The brokerage maintained its FY21, FY22 and FY23 estimates, but expects earnings to flatten in FY23 because the benefits driven by the pandemic will by then taper off. Jhunjhunwala more than halved his holding in FSL to 1.29 per cent in Q3 from 2.88 per cent in the September quarter.

The nearly 40 per cent rally in the shares in the October-December quarter and 393 per cent since the March low of Rs 20.10, could be a key reason for the stake sale. Anand Rathi in its Q3 earnings preview said it expected another quarter of revenue surprise from the company.

“The mortgage business continues to do well and margins are likely to benefit from revenue growth and the strong British pound tailwind,” it said.

Jhunjhunwala holds a stake in more than 30 listed firms.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Jubilant Life Sciences
First Published: Tue, January 12 2021. 23:23 IST
RECOMMENDED FOR YOU